An Agent Architecture for Concurrent Bilateral Negotiations

Abstract. We present an architecture that makes use of symbolic decision-making to support agents participating in concurrent bilateral negotiations. The architecture is a revised version of previous work with the KGP model [23, 12], which we specialise with knowledge about the agent’s self, the negotiation opponents and the environment. Our work combines the specification of domain-independent decision-making with a new protocol for concurrent negotiation that revisits the well-known alternating offers protocol [22]. We show how the decision-making can be specialised to represent the agent’s strategies, utilities and prefer-ences using a Prolog-like meta-program. The work prepares the ground for supporting decision-making in concurrent bilateral negotiations that is more lightweight than previous work and contributes towards a fully developed model of the architecture

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Understanding mechanism design—part 2 of 3: The Vickrey-Clarke-Groves mechanism

As we saw in the first part of this short series, a mechanism design problem involves engineering the rules of a game so that, if participants then behave rationally in the game (by choosing strategies that maximize their expected utility, for example), then the result will satisfy some desired property. So far, however, we have said nothing about what these desirable properties might be, or what mechanisms might achieve them. Here, we will dig into these two issues in a little more detail

Iterative voting and acyclic games

Multi-agent decision problems, in which independent agents have to agree on a joint plan of action or allocation of resources, are central to artificial intelligence. In such situations, agents' individual preferences over available alternatives may vary, and they may try to reconcile these differences by voting. We consider scenarios where voters cannot coordinate their actions, but are allowed to change their vote after observing the current outcome, as is often the case both in offline committees and in online voting. Specifically, we are interested in identifying conditions under which such iterative voting processes are guaranteed to converge to a Nash equilibrium state—that is, under which this process is acyclic. We classify convergence results based on the underlying assumptions about the agent scheduler (the order in which the agents take their actions) and the action scheduler (the actions available to the agents at each step). By so doing, we position iterative voting models within the general framework of acyclic games and game forms. In more detail, our main technical results provide a complete picture of conditions for acyclicity in several variations of Plurality voting. In particular, we show that (a) under the traditional lexicographic tie-breaking, the game converges from any state and for any order of agents, under a weak restriction on voters' actions; and that (b) Plurality with randomized tie-breaking is not guaranteed to converge under arbitrary agent schedulers, but there is always some path of better replies from any initial state of the game to a Nash equilibrium. We thus show a first separation between order-free acyclicity and weak acyclicity of game forms, thereby settling an open question from [Kukushkin 2011]. In addition, we refute another conjecture of Kukushkin regarding strongly acyclic voting rules, by proving the existence of strongly acyclic separable game forms

Strategyproof peer selection using randomization, partitioning, and apportionment

Peer reviews, evaluations, and selections are a fundamental aspect of modern science. Funding bodies the world over employ experts to review and select the best proposals from those submitted for funding. The problem of peer selection, however, is much more general: a professional society may want to give a subset of its members awards based on the opinions of all members; an instructor for a Massive Open Online Course (MOOC) or an online course may want to crowdsource grading; or a marketing company may select ideas from group brainstorming sessions based on peer evaluation. We make three fundamental contributions to the study of peer selection, a specific type of group decision-making problem, studied in computer science, economics, and political science. First, we propose a novel mechanism that is strategyproof, i.e., agents cannot benefit by reporting insincere valuations. Second, we demonstrate the effectiveness of our mechanism by a comprehensive simulation-based comparison with a suite of mechanisms found in the literature. Finally, our mechanism employs a randomized rounding technique that is of independent interest, as it solves the apportionment problem that arises in various settings where discrete resources such as parliamentary representation slots need to be divided proportionally